REG - e-Therapeutics plc - Change of Adviser

E-TherapeuticsAnnouncement

01/03/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20210301:nRSA5948Qa&default-theme=true

RNS Number : 5948Q  e-Therapeutics plc  01 March 2021

 

e-therapeutics plc

("e-therapeutics" or the "Company")

Change of Adviser

 

Oxford, UK, 1 March 2021 - e-therapeutics plc (AIM: ETX) is pleased to
announce the appointment of SP Angel Corporate Finance LLP as the Company's
Nominated Adviser and Broker, with immediate effect.

Director Disclosure

The Company also announces the following additional information in accordance
with paragraph (g) of Schedule Two to the AIM Rules for Companies in respect
of Ali Mortazavi, CEO of the Company. Mr Mortazavi is a current LLP Member of
Arcade Films 4 LLP and was at the time of his appointment to the Board on 11
February 2020.

 

Enquiries:

 e-therapeutics plc
 Ali Mortazavi, CEO                                 Tel: +44 (0)1993 883 125
                                                    www.etherapeutics.co.uk

 SP Angel Corporate Finance LLP                     Tel: +44(0)20 3470 0470
 Nominated Adviser and Broker
 Matthew Johnson/Caroline Rowe (Corporate Finance)
 Vadim Alexandre/Rob Rees (Corporate Broking)

 

About e-therapeutics plc

e-therapeutics plc is an Oxford, UK-based company with a powerful
computer-based approach to drug discovery, founded on its industry-leading
expertise in network biology to fully capture disease complexity. The Company
combines network science, machine learning, artificial intelligence,
statistics and big data with expertise in drug discovery and development to
transform the search for new medicines and intervention strategies.

e-therapeutics has developed an in silico laboratory that enables the rapid
screening of millions of compounds and the identification of small sub-sets
that are enriched for highly active hits. Its proprietary platform also has
novel applications in functional genomics, being able to analyse complex
genetic datasets, provide a deep understanding of pathological mechanisms and
distil actionable insights for the discovery of novel drugs, biomarkers and
diagnostics.

e-therapeutics has deployed and validated its disease-agnostic drug discovery
platform both in house and with partners, including Novo Nordisk, Galapagos NV
and a US-based, top 5 pharmaceutical company.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  APPBQLLLFLLXBBV